Zobrazeno 1 - 10 of 51 pro vyhledávání: '"Glen D. Raffel"'
2
Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ('5 + 1') induction chemotherapy regimen in newly diagnosed acute myeloid leukemia
Autor: Angela Desmond, Muthalagu Ramanathan, Jayde Bednarik, Rajneesh Nath, Neeraj Saini, Imran Puthawala, Glen D. Raffel, Jan Cerny, Zheng Zhou, Lindsey Shanahan, Vanessa Fiorini Furtado, Patricia M. Miron, Bruce A. Woda
Publikováno v: American Journal of Hematology. 94:209-215
An intensive "5 + 1" regimen, which included bolus high dose cytarabine (HiDAC) at 3 g/m2 once daily over 3 hours on days 1-5 and high dose mitoxantrone (HDM) 80 mg/m2 on day 2, was evaluated in 101 consecutively treated newly diagnosed acute myeloid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0a4bf0ba24269fe004e42b4dea9ad7
https://doi.org/10.1002/ajh.25347
Zobrazit plný text záznamu
3
FRI0235 PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILISATION AND COLLECTION OF CD34+ HAEMATOPOIETIC STEM CELLS WITHOUT G-CSF
Autor: Veit Schmelmer, J. Neale, David T. Scadden, Michael P. Cooke, Glen D. Raffel, Dwight M. Morrow, Jonathan Hoggatt, Jacky Davis, Kevin A. Goncalves, T. Boitano, John F. DiPersio, Haley Howell, William J. Savage, Patrick C. Falahee, Steven M. Devine
Publikováno v: Annals of the Rheumatic Diseases. 79:701-702
Background:Autologous haematopoietic stem cell (HSC) transplantation is a recommended therapeutic option for selected patients with autoimmune diseases. G-CSF mobilisation of HSCs requires 4-7 days of injections that are associated with significant s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9afbb0148e3544d61e5cdca11636707b
https://doi.org/10.1136/annrheumdis-2020-eular.3750
Zobrazit plný text záznamu
6
Mgta-456 Cell Therapy in Inherited Metabolic Disease (IMD) Yields Rapid and Durable Long-Term Improvement of Disease-Specific Outcomes in a Phase 2 Trial
Autor: Troy C. Lund, Anthony E. Boitano, John C. Davis, Michael P. Cooke, Jennifer A. Braun, Carolyn E.H. Condon, Ashish Gupta, Ryan Shanley, Paul J. Orchard, Glen D. Raffel, John E. Wagner
Publikováno v: Biology of Blood and Marrow Transplantation. 26:S19
Background Hematopoietic stem cell transplant (HSCT) in IMDs prevents progression of fatal neurodegeneration. Cord blood as a preferred donor source is disadvantaged by delayed engraftment and graft failure due to low CD34+ cell numbers. Higher cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49829a59ea26f7e6e36aa83d04a4b096
https://doi.org/10.1016/j.bbmt.2019.12.084
Zobrazit plný text záznamu
7
Robust Engraftment with Mgta-456, a CD34+ Expanded Cell Therapy Product in Patients with Inherited Metabolic Disorders (IMD): Preliminary Phase 2 Trial Results
Autor: Paul J. Orchard, Ashish Gupta, Troy C. Lund, Michael P. Cooke, John E. Wagner, Anthony E. Boitano, Glen D. Raffel, Jennifer A. Braun, Carolyn Eh Condon, Catherine A. Monaghan, John C. Davis, Ryan Shanley
Publikováno v: Biology of Blood and Marrow Transplantation. 25:S91-S92
Background Mucopolysaccharidosis type IH (MPS1/Hurler Syndrome), cerebral adrenoleukodystrophy (cALD), metachromatic leukodystrophy (MLD) and globoid cell leukodystrophy (GLD) are fatal IMDs affecting the central nervous system treatable through allo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1002b9e86b5b976caa88670e800193b0
https://doi.org/10.1016/j.bbmt.2018.12.171
Zobrazit plný text záznamu
9
Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor
Autor: Lukasz Biernat, Dwight M. Morrow, Veit Schmelmer, Patrick C. Falahee, Jason Neale, Kevin A. Goncalves, Glen D. Raffel, Michael P. Cooke, John F. DiPersio, John C. Davis, Steven M. Devine, Jonathan Hoggatt, Haley Howell, Anthony E. Boitano
Publikováno v: Blood. 134:1961-1961
Background Granulocyte colony-stimulating factor (G-CSF) is the standard of care for mobilization of hematopoietic stem cells (HSCs). G-CSF requires 4-7 days of injections and often multiple aphereses to acquire sufficient CD34+ cells for transplant.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a42662862eea8189dd12b64defb8d317
https://doi.org/10.1182/blood-2019-127523
Zobrazit plný text záznamu
10
Haploidentical (HAPLO) Vs Umbilical Cord Blood (UCB) Allogeneic Hematopoieitc Cell Transplant (ALLO-HCT) in Patients ≥ 60 Years with Hematological Malignancies
Autor: Muthalagu Ramanathan, Rajneesh Nath, Sakiko Suzuki, Jan Cerny, Glen D. Raffel, Zeina Al-Mansour, Jonathan M. Gerber
Publikováno v: Biology of Blood and Marrow Transplantation. 25:S213
Introduction Allo HCT is a curative option for many aggressive hematological malignancies that increase with age. HAPLO donors and UCB are alternative sources of hematopietic cells for patients lacking a matched sibling or unrelated donor. The choice
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8a8e4e542dc77e49e0d01ad7a11f6b3
https://doi.org/10.1016/j.bbmt.2018.12.290
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje